Bispecific T-cell engaging antibodies in B-cell precursor acute lymphoblastic leukemias: focus on blinatumomab

Bispecific T-cell engaging antibodies are constructs engineered to bind to two different antigens, one to a tumor-specific target and the other to CD3-positive T cells or natural killer (NK) cells. Blinatumomab engages CD19 and CD3, performing effective serial lysis. The clinical development program...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribera, Jose-Maria, Genescà, Eulalia, Ribera, Jordi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236391/
https://www.ncbi.nlm.nih.gov/pubmed/32523659
http://dx.doi.org/10.1177/2040620720919632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236391/
https://www.ncbi.nlm.nih.gov/pubmed/32523659
http://dx.doi.org/10.1177/2040620720919632

Ejemplares similares